Pain
Conditions
Brief summary
The purpose of the study is to evaluate the routes and rate of elimination and recovery of total radioactivity (TRA) and characterize the Pharmacokinetic (PK) of VX-993 after a single oral dose of 14C-VX-993.
Detailed description
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)
Interventions
DRUG14C-VX-993
Solution for Oral Administration.
Sponsors
Vertex Pharmaceuticals Incorporated
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive * A total body weight of more than (\>) 50 kg * Participants must have at least 1 regular bowel movement per day Key
Exclusion criteria
* History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug * Any condition possibly affecting drug absorption, distribution, metabolism, or excretion * Exposure to any non-environmental radiation within 12 months of dosing * Participation in more than 1 radiolabeled study (if prior radiation exposure unknown) or participation in more than 3 radiolabeled studies (if radiation exposure known) in the 12 months before dosing or if the annual whole body radiation exposure from previous studies (including this dosing) exceeds FDA-allowed maximum whole body radiation exposure of 5000 mrem Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amount of VX-993 and Metabolites, Expressed as a percent of TRA, in Plasma, Urine and Feces | From Day 1 up to Day 25 |
| Apparent Clearance (CL/F) of VX-993 in Plasma | From Day 1 up to Day 25 |
| Maximum Observed Plasma Concentration (Cmax) of VX-993 in Plasma | From Day 1 up to Day 25 |
| Time for VX-993 to Reach Maximum Concentration (Tmax) in Plasma | From Day 1 up to Day 25 |
| Terminal Phase Rate Constant (λz) of Total Radioactivity (TRA) in Whole blood and Plasma | From Day 1 up to Day 25 |
| Amount of Radioactivity Excreted (Ae) of TRA in Urine, Feces and Vomitus (if applicable) | Pre dose up to Day 25 |
| AUC0-tlast of TRA in Whole blood and Plasma | From Day 1 up to Day 25 |
| AUC0-inf of TRA in Whole blood and Plasma | From Day 1 up to Day 25 |
| CL/F of TRA in Whole blood and Plasma | From Day 1 up to Day 25 |
| Renal Clearance (CLr) of TRA in Urine and Feces | Pre dose up to Day 25 |
| Cmax of TRA in Whole blood and Plasma | From Day 1 up to Day 25 |
| Fraction (percent) of Dose Excreted Unchanged in Urine of TRA | Pre dose up to Day 25 |
| Tmax of TRA in Whole blood and Plasma | From Day 1 up to Day 25 |
| Apparent Volume of Distribution (Based on the Terminal Phase) of TRA in Whole blood and Plasma | From Day 1 up to Day 25 |
| Apparent Volume of Distribution (Vz/F) (Based on the Terminal Phase) of VX-993 in Plasma | From Day 1 up to Day 25 |
| Terminal Phase Rate Constant (λz) of VX-993 in Plasma | From Day 1 up to Day 25 |
| Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of VX-993 in Plasma | From Day 1 up to Day 25 |
| Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-993 in Plasma | From Day 1 up to Day 25 |
Secondary
| Measure | Time frame |
|---|---|
| Terminal Phase Rate Constant (λz) of VX-993 Metabolites in Plasma and Urine (if applicable) | From Day 1 up to Day 25 |
| Amount of radioactivity excreted (Ae) of VX-993 Metabolites in Urine and Feces | Pre dose up to Day 25 |
| AUC0-last of VX-993 Metabolites in Plasma | From Day 1 up to Day 25 |
| AUC0-inf of VX-993 Metabolites in Plasma | From Day 1 up to Day 25 |
| CL/F of VX-993 Metabolites in Plasma | From Day 1 up to Day 25 |
| CLr of VX-993 Metabolites in Urine | From Day 1 up to Day 25 |
| Cmax of VX-993 Metabolites in Plasma | From Day 1 up to Day 25 |
| Fraction (percent) of Dose Excreted Unchanged in Urine of VX-993 Metabolites | Pre dose up to Day 25 |
| Tmax of VX-993 Metabolites in Plasma | Day 1 up to Day 25 |
| Apparent Volume of Distribution (Based on the Terminal Phase) of VX-993 Metabolites in Plasma | Day 1 up to Day 25 |
| Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Day 1 up to Day 35 |
| Safety and Tolerability as Assessed by Number of Participants With Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses | Pre-dose up to Day 35 |
| Metabolite Profiling and Identification in Plasma, Urine, and Feces | From Day 1 up to Day 25 |
Countries
United States
Outcome results
None listed